fbpx

scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)

BURLINGTON, MA, November 2, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date of June 23, 2018.

about scpharmaceuticals
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous (IV) delivery.

contacts
Investor Relations for scPharmaceuticals, Inc.:
Katherine Taudvin, 781-301-6706
ktaudvin@scpharma.com

Nyheder

90 mio. kr. til 18 talentfulde forskere
19. oktober 2020
Søren Dinesen Lumdbeckfonden
Psykiatriforskning udløser stor videnskabelig pris
13. oktober 2020
Christian Sandøe Musaeus Lundbeckfonden
Han satser på demensområdet
13. oktober 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge